Humanized anti-CD200 antibodies and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11802154
APP PUB NO 20210230273A1
SERIAL NO

16954562

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided herein are antibodies, or antigen binding portions thereof, that bind to CD200. Also provided are uses of these proteins in therapeutic applications, such as the treatment of cancer and in conjunction with organ transplantation. Also provided are nucleic acids encoding the heavy and/or light chain variable regions (or heavy and/or light chains) of the antibodies, vectors comprising the nucleic acids, and cells that produce the antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ALEXION PHARMACEUTICALS, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Mack, Taneisha Ann-Tanara East Hampton, US 4 1
Panavas, Tadas Madison, US 2 0
Sheridan, Douglas L Branford, US 28 259

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Apr 30, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 30, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 30, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00